公开(公告)号：US20220315656A1

公开(公告)日：2022-10-06

申请号：US17740100

申请日：2022-05-09

Applicant: Alector LLC

Inventor： Kate MONROE ,  Helen LAM ,  Patricia CULP ,  Arnon ROSENTHAL

IPC: C07K16/28 ,  A61P37/00 ,  A61P25/28 ,  A61P31/04 ,  A61P25/00 ,  A61P25/08 ,  A61P29/00 ,  A61P35/00

Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Siglec-5 protein, e.g., human Siglec-5 or a mammalian Siglec-5, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

公开(公告)号：US20220251219A1

公开(公告)日：2022-08-11

申请号：US17721112

申请日：2022-04-14

Applicant: Alector LLC

Inventor： Arnon ROSENTHAL ,  Tina SCHWABE ,  Michael KURNELLAS ,  Robert PEJCHAL ,  Anthony B. COOPER

IPC: C07K16/28 ,  A61K31/7088

Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Sortilin protein, e.g., human Sortilin or a mammalian Sortilin, and use of such compostions in preventing, reducing risk, or treating an individual in need thereof.

公开(公告)号：US20220185899A1

公开(公告)日：2022-06-16

申请号：US17534291

申请日：2021-11-23

Applicant: Alector LLC

Inventor： Arnon ROSENTHAL ,  Tina SCHWABE ,  Michael KURNELLAS ,  Robert PEJCHAL ,  Anthony B. COOPER

IPC: C07K16/28 ,  A61K31/7088

Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Sortilin protein, e.g., human Sortilin or a mammalian Sortilin, and use of such compostions in preventing, reducing risk, or treating an individual in need thereof.

公开(公告)号：US20220162309A1

公开(公告)日：2022-05-26

申请号：US17581471

申请日：2022-01-21

Applicant: Alector LLC

Inventor： Patricia CULP ,  Helen LAM ,  Arnon ROSENTHAL ,  Seung-Joo LEE ,  Nels P. NIELSON ,  Robert PEJCHAL

IPC: C07K16/28 ,  C07K16/46

Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a CD33 protein, e.g., human CD33 or a mammalian CD33, and have improved and/or enhanced functional characteristics, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

公开(公告)号：US20220000083A1

公开(公告)日：2022-01-06

申请号：US17475116

申请日：2021-09-14

Applicant: Alector LLC

Inventor： Arnon ROSENTHAL ,  Seung-Joo LEE

IPC: A01K67/027 ,  C12N15/85 ,  C07K14/705

Abstract: Provided herein are transgenic non-human animals whose genomes comprise two or more human genes selected from CD33, Siglec-5, Siglec-7, Siglec-9, Siglec-11, Siglec-14, and Siglec-16, to methods of screening candidate agents that bind to and/or modulate the function and/or activity of at least one of the human genes in the transgenic non-human animals, and to methods of screening candidate agents to determine their effect on one or more activities and/or functions associated with expression of at least one of the human genes in the transgenic non-human animals. Further provided herein are methods of recapitulating a human Siglec immune system in a non-human animal, and methods of generating a non-human animal disease model comprising a human Siglec repertoire.

公开(公告)号：US20210395361A1

公开(公告)日：2021-12-23

申请号：US17263534

申请日：2019-07-26

Applicant: Alector LLC

Inventor： Patricia CULP ,  Rashmi BANKOTI ,  Helen LAM ,  Arnon ROSENTHAL

IPC: C07K16/28 ,  A61K47/68 ,  A61P35/00

Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind a Siglec-5 protein, e.g., human Siglec-5, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

公开(公告)号：US11147249B2

公开(公告)日：2021-10-19

申请号：US15836089

申请日：2017-12-08

Applicant: ALECTOR LLC

Inventor： Arnon Rosenthal ,  Seung-Joo Lee

IPC: A01K67/027 ,  C12N15/85 ,  C07K14/705

Abstract: Provided herein are transgenic non-human animals whose genomes comprise two or more human genes selected from CD33, Siglec-5, Siglec-7, Siglec-9, Siglec-11, Siglec-14, and Siglec-16, to methods of screening candidate agents that bind to and/or modulate the function and/or activity of at least one of the human genes in the transgenic non-human animals, and to methods of screening candidate agents to determine their effect on one or more activities and/or functions associated with expression of at least one of the human genes in the transgenic non-human animals. Further provided herein are methods of recapitulating a human Siglec immune system in a non-human animal, and methods of generating a non-human animal disease model comprising a human Siglec repertoire.

公开(公告)号：US20210139581A1

公开(公告)日：2021-05-13

申请号：US16869315

申请日：2020-05-07

Applicant: ALECTOR LLC

Inventor： Patricia CULP ,  Helen LAM ,  Arnon ROSENTHAL ,  Seung-Joo LEE ,  Nels P. NIELSON ,  Robert PEJCHAL

IPC: C07K16/28 ,  C07K16/46

Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a CD33 protein, e.g., human CD33 or a mammalian CD33, and have improved and/or enhanced functional characteristics, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.

公开(公告)号：US10849992B1

公开(公告)日：2020-12-01

申请号：US15565063

申请日：2016-04-07

Applicant: ALECTOR LLC

Inventor： Arnon Rosenthal ,  Tina Schwabe

IPC: G01N33/53 ,  A61K49/00 ,  G01N33/533 ,  G01N33/542 ,  C07K16/28 ,  G01N21/64

Abstract: The present disclosure provides methods of screening for a sortilin binding antagonist. In some embodiments, the methods include incubating an agent with a sortilin protein and a sortilin ligand, where the sortilin protein and sortilin ligand are each attached to a member of a fluorescence donor/acceptor pair, exciting the fluorescence donor of the fluorescence donor/acceptor pair, and detecting fluorescence emitted by the fluorescence donor at a second wavelength and fluorescence emitted by the fluorescence acceptor at a third wavelength. A decrease in the ratio of the fluorescence emitted by the fluorescence acceptor at the third wavelength to the fluorescence emitted by the fluorescence donor at the second wavelength, as compared to the ratio in the absence of the agent, indicates that the agent is a sortilin binding antagonist.

公开(公告)号：US10800844B2

公开(公告)日：2020-10-13

申请号：US15772010

申请日：2016-10-28

Applicant: ALECTOR LLC

Inventor： Arnon Rosenthal ,  Kate Monroe ,  Seung-Joo Lee

IPC: C07K16/28 ,  A61P31/04 ,  A61P25/00 ,  A61P29/00 ,  A61P35/00 ,  A61K39/395 ,  A61K45/06 ,  A61K39/00

Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a Siglec-9 protein, e.g., human Siglec-9 or a mammalian Siglec-9, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.